	US 12,473,599 B2
	Gene signatures for predicting metastasis of melanoma and patient prognosis
Alexander Meves, Rochester, MN (US); and Domenico Bellomo, The Hague (NL)
Assigned to SkylineDx B.V., Rotterdam (NL); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/262,175
Filed by SkylineDx B.V., Rotterdam (NL); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Jul. 25, 2019, PCT No. PCT/NL2019/050487 § 371(c)(1), (2) Date Jan. 21, 2021, PCT Pub. No. WO2020/022895, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/778,777, filed on Dec. 12, 2018.
Claims priority of provisional application 62/750,294, filed on Oct. 25, 2018.
Claims priority of provisional application 62/703,221, filed on Jul. 25, 2018.
Prior Publication US 2021/0301353 A1, Sep. 30, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/686 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/166 (2013.01)]

14 Claims

1. A method for treating an individual afflicted with primary cutaneous melanoma, the method comprising:

determining in a sample from the individual a gene expression signature comprising ITGB3, PLAT, GDF15, IL8, and at least three genes selected from MLANA, LOXL4, SERPINE2, and TGFBR1,

classifying the individual as having a metastasis-positive sentinel lymph node based upon the gene expression signature, and

treating the individual by providing a cancer treatment to the individual,

wherein the cancer treatment comprises administration of an antibody selected from the group consisting of ipilimumab, nivolumab, and pembrolizumab.